- Home
- OSS vs IKT Comparison
OSS vs IKT Comparison
Compare OSS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSS | IKT |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.6M | 240.1M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OSS | IKT |
|---|---|---|
| Price | $15.69 | $2.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $10.00 | $5.00 |
| AVG Volume (30 Days) | ★ 2.1M | 932.0K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,027,382.00 | N/A |
| Revenue This Year | $22.19 | N/A |
| Revenue Next Year | $20.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.46 | N/A |
| 52 Week Low | $2.37 | $1.33 |
| 52 Week High | $16.95 | $2.27 |
Technical Indicators
Market Signals| Indicator | OSS | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 79.00 | 62.80 |
| Support Level | $7.45 | $1.43 |
| Resistance Level | N/A | $2.12 |
| Average True Range (ATR) | 1.37 | 0.10 |
| MACD | 0.70 | 0.02 |
| Stochastic Oscillator | 85.46 | 81.53 |
Price Performance
Historical ComparisonAbout OSS One Stop Systems Inc.
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.